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Abstract 
 
Background: With recent changes in UK clinical practice for diabetes care, contemporary 
estimates of sex disparities in cardiovascular risk and risk factor management are needed.  
Methods: In this retrospective cohort study, using the Clinical Practice Research Datalink 
linked to hospital and death records for people in England, we identified 79,985 patients with 
incident T2DM between 2006-2013 matched to 386,547 patients without diabetes. Sex-
stratified Cox models were used to assess cardiovascular risk. 
Results: Compared to women without T2DM, women with T2DM had a higher 
cardiovascular event risk (adjusted HR 1.20 [95% CI 1.12-1.28]) with similar corresponding 
data in men (HR 1.12 [1.06-1.19]) leading to a non-significant higher relative risk in women 
(risk ratio 1.07 [0.98-1.17]). However, some important sex differences in the management of 
risk factors were observed. Compared to men with T2DM, women with T2DM were more 
likely to be obese, hypertensive and have hypercholesterolaemia but were less likely to be 
prescribed lipid-lowering medication and ACE inhibitors, especially if they had CVD.  
 
Conclusions: Compared to men developing T2DM, women with T2DM do not have a 
significantly higher relative increase in cardiovascular risk, but ongoing sex disparities in 
prescribing should prompt heightened efforts to improve the standard and equity of diabetes 
care in women and men. 
 
Keywords: sex-specific; cardiovascular disease risk factors; cardiovascular outcomes; type 2 
diabetes mellitus; database
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Clinical Perspective 
 
1) What is new? 
 In contrast to earlier studies, in this large contemporary cohort we showed no 
significant gender disparities in CVD risk associated with the development of T2DM. 
 Important sex differences in the management of risk factors remained: women with 
T2DM were more likely to be obese, have hypercholesterolemia and hypertension and 
were less likely to be prescribed statins and ACE inhibitors, especially if they had 
CVD. 
 In T2DM subgroups with CVD, women were less likely to receive antiplatelet agents 
than men. 
 
2) What are the clinical implications? 
 The observed gender biases in risk factor management highlight the need for closer 
adherence to prescribing guidance, continued routine surveillance for gender-related 
prescribing biases and possibly greater uptake of professional-based interventions in 
the community supporting the provision of high-quality equitable care. 
 Particular attention is required for women with abnormal cardiovascular risk factors, 
who may be receiving suboptimal preventative care. 
1 
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INTRODUCTION  
Cardiovascular disease (CVD) is the leading cause of death in people with diabetes.1,2 Four 
large meta-analyses showed that after developing diabetes, the increase in the risk for fatal 
coronary heart disease, stroke or other atherosclerotic death was 27-50% higher for women 
than men.3–6 The mechanism behind this sex disparity is still unclear but growing evidence 
suggests that the development of type 2 diabetes (T2DM) could adversely affect metabolic 
and CVD risk factor profiles more in women than men.7,8 Some of the excess risk observed in 
women could be explained by suboptimal and less aggressive CVD risk factor management, 
particularly after acute myocardial infarction;7–12 however, these previous studies lacked 
sufficient data to assess this.3–5  
 
As the majority of studies examining  sex disparities in CVD risk in diabetes are now over a 
decade old (1960-2005)3–5, these estimates may not be relevant for contemporary practice. 
With a UK pay-for-performance scheme (Quality and Outcomes Framework; QOF) 
introduced in general practice in 2004 to improve diabetes care, the recording and monitoring 
of disease management has greatly improved over time and this is likely to have contributed 
to the year-on-year reductions in risk for fatal and non-fatal CVD events.13–16 
 
Our primary aim was to determine if sex disparities in CVD risk associated with T2DM are 
evident in a contemporary national cohort. Our secondary aim was to investigate the extent of 
any sex differences in the management of CVD risk factors and if these differences explain 
any disparities in CVD risk. Our hypotheses were that there would be no sex disparities in 
cardiovascular risk or risk factor management. 
 
METHODS 
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Ethical Approval 
This study is based in part on data from the Clinical Practice Research Datalink obtained 
under licence from the UK Medicines and Healthcare products Regulatory Agency. The data 
is provided by patients and collected by the NHS as part of their care and support. ONS and 
HES data is subject to Crown copyright (2018) protection, re-used with the permission of The 
Health, & Social Care Information Centre, all rights reserved. The OPCS Classification of 
Interventions and Procedures, codes, terms and text is Crown copyright (2016) published by 
Health and Social Care Information Centre, also known as NHS Digital and licensed under 
the Open Government Licence available at www.nationalarchives.gov.uk/doc/open-
government-licence/open-government-licence.htm. The interpretation and conclusions 
contained in this study are those of the authors alone. The study was approved by the 
Independent Scientific Advisory Committee (ISAC) for CPRD research, ref. 15_123Mn.  
 
Data Sharing 
 Read and ICD codes used are publicly available at The ClinicalCodes repository17 and can 
be accessed at  https://clinicalcodes.rss.mhs.man.ac.uk/. Electronic health records are, by 
definition, considered “sensitive” data in the UK by the Data Protection Act and cannot be 
shared via public deposition because of information governance restriction in place to protect 
patient confidentiality. Access to data is available only once approval has been obtained 
through the individual constituent entities controlling access to the data. The primary care 
data can be requested via application to the Clinical Practice Research Datalink 
(https://www.cprd.com); secondary care data can be requested via application to the hospital 
episode statistics from the UK Health and Social Care Information Centre 
(www.hscic.gov.uk/hesdata); and mortality data are available by application to the UK Office 
for National Statistics (www.ons.gov.uk/ons/index.html). 
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Data Source 
This retrospective population-based cohort study used data from the Clinical Practice 
Research Datalink (CPRD), an anonymised, longitudinal primary care medical record 
database of UK general practices.18 In 2015, the CPRD contained data on over 4.4 million 
active (alive, currently registered) patients from 674 registered general practices, equating to 
approximately 6.9% of the UK population.18 Patients are broadly representative of the general 
population in terms of age, sex, and ethnicity.18 The CPRD dataset was linked at the patient-
level to hospitalisation data (Hospital Episode Statistics, HES), national mortality data 
(Office for National Statistics, ONS) and deprivation data, for all eligible patients in 380 
linkage-consenting English practices. More detailed information on linkage is available in the 
Supplemental Methods.  
 
Study Population 
Incident T2DM cases were identified from Read codes in the electronic health record, if their 
first diagnostic code for diabetes (type 1 diabetes or type 2 diabetes) was recorded between 
01/01/2006-31/12/2013, with no diagnoses prior to this date. We used a validated algorithm 
to classify patients with T2DM based on diabetes codes, treatments, age, BMI and ethnicity.19 
The application of this algorithm using CPRD data has been described previously.20 The 
index date in the T2DM cohort was defined as the first diagnostic code within the study 
window. 
 
Patients with T2DM were matched (individual matching for categorical variables and caliper 
matching for continuous variables) with up to five controls without diabetes on year of birth 
(± 2 years), sex, and general practice. Patients with T2DM without any matched controls 
were excluded (6.9%). Individuals with T2DM and controls without diabetes were required to 
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have at least 1 year prior registration within the practice. All participants were observed from 
the index date to the endpoint date, study end date (31/03/2015), practice’s last data 
collection date, death, or transfer out of practice.  
 
Figure 1 outlines the study populations included at each analytical phase. In phase 2, risk of 
incident major adverse cardiac events (MACE) associated with diabetes, individuals with a 
history of cardiovascular disease were excluded. In phase 3, management of risk factors in 
diabetes, all individuals diagnosed with type 2 diabetes (with or without a history of CVD) 
were included. 
 
Cardiovascular Outcomes 
The primary endpoint was the first record of the following major adverse cardiac events 
(MACE) after the diagnosis of diabetes, identified from primary care (Read codes), HES data 
(ICD-10 codes) or ONS death data (ICD-10 codes): myocardial infarction (MI), stroke and 
cardiovascular death. Our secondary endpoints were: 1) fatal and non-fatal MI and 2) fatal 
and non-fatal stroke. 
 
Patient Demographics and Baseline Clinical Characteristics 
Ethnicity was identified from primary care records using Read codes and through linkage 
with HES as described previously.20 Deprivation data was defined using the Index of 
Multiple Deprivation (IMD) 2010 classification at the level of the patient’s residential 
postcode; categorised into five quintiles: IMD 1 (least deprived) to IMD 5 (most deprived). 
 
Baseline data for obesity, HbA1c, blood pressure, hypercholesterolaemia (elevated total and 
LDL cholesterol), chronic kidney disease (stage 3 and above), microalbuminuria and 
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proteinuria were captured as the closest measure up to 6 months before and 3 months after the 
index date (diabetes diagnosis date or corresponding date for controls). Further details on the 
definitions of these variables are provided in the Supplemental Methods. Cardiovascular 
disease (including MI, coronary heart disease, stroke, transient ischaemic attack, peripheral 
vascular disease and cardiac arrest), neuropathy and retinopathy were defined using Read 
codes, up to the index date. Smoking status (current, former or never) was defined according 
to the closest recording before the index date.  
 
Recorded HbA1c, blood pressure and cholesterol measurements were used to define risk 
factor control at baseline (further details are provided in the Supplemental Methods).  
 
Patient Management Variables 
To examine management in people with diabetes, we considered the frequency of risk factor 
checks, consultations with a healthcare professional within primary care, interventions 
offered and prescriptions for relevant medications. Risk factor observations included HbA1c 
tests, blood pressure checks, lipid checks, BMI measured and smoking cessation discussions 
recorded. Consultations were defined into two main categories: face-to-face interactions and 
telephone interactions with a healthcare professional. Interventions offered were classified 
into diet intervention, exercise intervention, structured education and bariatric surgery. Drug 
prescriptions included diabetes therapies, antihypertensive agents, lipid-lowering therapies 
and antiplatelet agents.  
 
Patient management variables were assessed at yearly intervals after the diabetes diagnosis 
date (index date) until patients’ exit from study (end of follow-up). These data were 
summarised for the following time periods: year 1 (up to 3 months prior to and 12 months 
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after the index date), years 2-3, years 4-5 and years 6-7. When patients had multiple measures 
recorded for biological variables within the time periods, the mean value was taken. 
Management variables were stratified and assessed by time-varying CVD status (with 
/without CVD during each follow-up time period). 
 
Minimum Standard of Care Indicators for Diabetes  
Nine standards of care were considered based on QOF indicators for diabetes management in 
general practice between 2006 and 2013.21,22 The minimum standard of care indicators 
included: recording of BMI, HbA1c and blood pressure in the previous 15 months; testing for 
eGFR/serum creatinine and microalbuminuria in the previous 15 months; HbA1c, blood 
pressure and total cholesterol levels below specific targets in the previous 15 months; and 
treatment for microalbuminuria/proteinuria. 
 
The indicators were assessed during the first 15 months of each follow-up time band 
following the diagnosis of diabetes (years 2-3, years 4-5 and years 6-7), in accordance with 
the QOF standards assessment period.  
 
Statistical Analysis 
Comparisons with T2DM and controls were sex-stratified for all analyses. In phase 1 of the 
study, baseline characteristics were summarised using mean (SD) and proportions as 
appropriate and comparisons by sex analysed using t-tests or chi-squared tests.  
 
For phase 2, individuals with a history of cardiovascular disease at baseline were excluded. 
Stratified Cox proportional hazards models, accounting for the matched pairs (up to 1:5 case 
control ratio) by allowing for distinct underlying hazard functions for each matched set 
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(stratum), estimated sex-specific hazard ratios (HR) for the primary and secondary outcomes 
in people with type 2 diabetes compared to controls without diabetes. Four models were 
constructed: 1) unadjusted, 2) adjusted for baseline calendar year, age, general practice, 
ethnicity, and deprivation, 3) additional adjustments for baseline smoking, obesity, 
hypertension, hypercholesterolaemia and Charlson Comorbidity Index (excluding diabetes 
and cardiovascular conditions; see the Supplemental Methods and Supplemental Table 1 for 
further details) and 4) adjustment for time-varying risk factors to capture intervention-related 
changes; smoking, obesity, hypertension, hypercholesterolaemia and raised HbA1c (>7% 
[53mmol/mol]). As additional covariates were adjusted for in the Cox models, inclusion of 
the matching factors in the models was required. The two-fold fully conditional specification 
algorithm for multiple imputation was used to impute longitudinal measurements for obesity, 
hypertension, hypercholesterolaemia and raised HbA1c (>7% [53 mmol/mol]); further details 
in the Supplemental Methods. The ratio of hazard ratios between women (DM vs. Non-DM) 
and men (DM vs. Non-DM) were calculated to estimate excess risk for CVD in women who 
developed diabetes compared to men who developed diabetes. The age-specific influence of 
diabetes on incident MACE events in women and men was estimated using unadjusted and 
multivariable-adjusted Cox models stratified by age of onset of diabetes (<50, 50-60, 60-70, 
≥70 years of age). As a sensitivity analysis, we compared risk estimates for diabetes 
diagnoses between an earlier and later time period (2007-2010 vs 2011-2013) within the 
study (further details in the Supplemental Material) and performed the unadjusted analysis on 
a prevalent type 2 diabetes cohort. 
 
In phase 3, within the diabetes cohort alone, including those with and without prevalent 
CVD, management variables were summarised as percentages or age-adjusted rates and 
multiple logistic regression models assessed sex differences in attainment of standard of care 
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indicators within follow-up time bands. As a sensitivity analysis, specific care indicators were 
stratified by CVD and age (details provided in the Supplemental Material).  
 
Time with poor control was calculated as the time from the first risk factor measurement 
above a specified threshold until either: 1) the first subsequent measurement below the 
threshold, 2) a change of drug regimen for the specific risk factor, or 3) end of follow-up; 
whichever came first. For all drug therapies, the change in drug regimen was defined as the 
addition of a new drug to the current regimen and for diabetes medication this included 
adding insulin or switching to insulin. For each risk factor, sex-stratified cumulative 
incidence plots were constructed for the time from the risk factor level being above the cut-
off to the time of drug intensification. The logrank test was used to determine if the 
probability of drug intensification occurring at any time point was significantly different in 
women and men; with a P-value<0.05 indicating a significant difference.  
 
Finally, in patients with T2DM, we assessed sex differences in times to drug intensification 
after risk factor levels exceed specified thresholds. 
 
Analyses were performed using Stata 15.1 (StataCorp LP, College Station, TX). 
 
RESULTS 
Phase 1: The cohort comprised of 79,985 patients with incident T2DM (44.3% women) and 
386,547 matched controls (44.8% women) with a mean ± SD follow-up of 3.6 ± 2.4 years 
and 3.5 ± 2.4 years, respectively. Participant characteristics at baseline are presented in Table 
1. At baseline, women with T2DM were 2-3 years older; more likely to be obese, have 
hypercholesterolaemia and chronic kidney disease than men with T2DM. Men with T2DM 
12 
 
were more likely to be current smokers and have higher HbA1c, hypertension, and diabetes-
related microvascular and macrovascular complications than women with T2DM. For both 
men and women with T2DM, those without CVD at the time of diabetes diagnosis had a 
worse risk factor profile than those with CVD, with a greater propensity for poorly-controlled 
HbA1c, hypertension and hypercholesterolaemia (Supplemental Table 2). Women with CVD 
at baseline were approximately 4 years older than men with CVD and were more likely to 
have lower HbA1c levels, but higher cholesterol and established kidney disease 
(Supplemental Table 2). 
 
Phase 2: During follow-up, MACE events occurred in 9,806 people with diabetes (12.3% 
overall; 11.6% of women and 12.8% of men) and 30,226 people without diabetes (7.8% 
overall; 7.4% of women and 8.1% of men); Supplemental Table 3. In individuals without a 
previous history of cardiovascular disease, incident MACE events occurred in 4,564 people 
with diabetes (7.2% overall; 7.0% of women and 7.3% of men) and 11,665 people without 
diabetes (4.2% overall; 4.1% of women and 4.3% of men); Supplemental Table 3. The 
estimated hazard ratio of experiencing an incident MACE event associated with diabetes, 
after adjusting for baseline factors (non-modifiable and modifiable), was 1.23 (95% CI 1.16-
1.32) for women and 1.17 (1.11-1.23) for men, leading to a non-significant excess risk in 
women (relative risk ratio 1.05 [95% CI 0.97-1.14]); Supplemental Table 4. After further 
adjusting for intervention-related changes in the modifiable risk factors in time-varying 
covariate-adjusted models, there remained no significant excess risk for MACE events in 
women compared to men (risk ratio: 1.07 [95% CI 0.98-1.17]); Supplemental Table 4 and 
Figure 2. Similar findings were observed when stratified by year of T2DM diagnosis 
(Supplemental Tables 5 and 6). 
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We examined the interaction between ethnicity and gender on CVD risk, which was not 
significant (not shown). An inverse association between age of onset of diabetes and risk of 
incident MACE events in women and men was observed, with the highest risk in those 
diagnosed with type 2 diabetes aged 50 or younger; HR 2.83 (95% CI 1.86-4.30) in women 
and HR 2.18 (95% CI 1.73-2.74) in men (Supplemental Table 7). The magnitude of the 
excess risk for MACE events in women compared to men was similar across all age bands, 
except in those aged over 70 where this attenuated; however, we did not identify any 
significant sex disparities in CVD risk within age groups (with the exception of those 
diagnosed with T2DM aged 60-70). 
 
Phase 3: Within the diabetes cohort (with/without prevalent CVD at baseline and during 
follow-up), we assessed rates of risk factor checks and consultations, the proportions with 
risk factor levels above target levels and proportions prescribed various medications for 
abnormal risk factors in patients at specific time points from diagnosis (Supplemental Table 
8). Management in men and women was broadly similar with some notable exceptions: a) 
compared to men, women had better glycaemic control; b) were more likely to be obese; c) 
have hypertensive end organ damage; and d) hypercholesterolaemia; but e) were less likely to 
be prescribed statin medication, despite having more frequent healthcare contacts.  
 
Men and women without CVD at baseline or diagnosed during follow-up were consistently 
more likely to be obese, have poorer glycaemic control, hypertension, hypercholesterolaemia, 
and substantially lower prescribing of antihypertensive agents, antiplatelets and lipid-
lowering medications than those with CVD (Supplemental Tables 9 and 10). Within patients 
without CVD, sex differences were observed with women more likely to have 
hypercholesterolaemia but with fewer prescriptions for lipid-lowering medications than men 
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(Supplemental Table 10). In those with CVD at diagnosis or diagnosed during follow-up, the 
proportion of women receiving statins, antiplatelet medications and the majority of 
antihypertensive drugs (with the exception of ARIIBs and diuretics) was lower compared to 
men (Supplemental Table 9).  
 
Performance against nine minimum care standards was assessed at different time intervals 
from the diabetes diagnosis (Supplemental Table 11). The proportion of women and men 
meeting each standard of care were comparable with a few exceptions in keeping with the 
above analysis: a) women were less likely than men to have a total cholesterol ≤ 5 mmol/l; 
and b) were less likely to be prescribed ACE inhibitors in the presence of proteinuria or 
microalbuminuria (Supplemental Table 11); c) women were also less likely than men to be 
prescribed statins (Supplemental Table 12). Sex differences in achieved cholesterol levels and 
treatment with statins were more obvious in those with prevalent CVD compared to those 
without CVD (Supplemental Tables 11 and 12) and especially in younger patients 
(Supplemental Table 12).  
 
Finally, in patients with T2DM, we assessed sex differences in times to drug intensification 
after risk factor levels exceed specified thresholds. These data indicated only modest sex 
differences in times to drug intensification (Figure 3; Supplemental Table 13): a) women with 
hypertension taking 0 or 1 antihypertensive agents were treated up to 1 month earlier than 
men on the same drug regimen. However, this modest early effect was not reflected in the 
probability of treatment intensification over 7 years (Supplemental Table 13) or when 
considering all hypertensive patients over the entire follow-up period (Figure 3); b) women 
with hypercholesterolemia and CVD were 10% less likely to be prescribed lipid lowering 
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medication Supplemental Table 13); c) there were no sex-related differences in the 
intensification of treatment for hyperglycaemia (Figure 3 and Supplemental Table 13).  
 
DISCUSSION 
In contrast to findings from earlier studies, in this large contemporary primary care-based 
cohort study in England, we found that women who developed T2DM did not have a 
significantly higher relative increase in their risk for CVD than men who develop T2DM, 
before or after adjusting for non-modifiable and modifiable risk factors. However, some 
important sex differences in the management of risk factors were observed. From onset of 
diabetes and in the subsequent years, compared to men with T2DM, women with T2DM had 
better glycaemic control but were more likely to have obesity, hypercholesterolaemia and 
hypertension and less likely to be prescribed lipid-lowering medication and ACE inhibitors, 
especially if they had CVD. In the T2DM subgroup, those without CVD at baseline or 
throughout follow-up consistently had worse risk factor control than those with CVD but had 
lower prescribing of antihypertensive agents, antiplatelets and lipid-lowering medications. In 
both subgroups with and without CVD, women were less likely to receive antiplatelet 
medications than men. 
 
Prior studies of sex disparities in CVD risk associated with developing type 2 diabetes 
Prior meta-analyses have shown that after developing diabetes, the increase in risk for fatal 
coronary heart disease, stroke or other atherosclerotic death was higher for women than men - 
with significant ratios of relative risks: 1.46 (95% CI: 1.14-1.88) for fatal coronary heart 
disease;5 1.44 (1.27-1.63) for incident coronary heart disease;3 1.27 (1.10-1.46) for stroke4; 
and 1.43 (1.27-1.61) for all fatal atherosclerotic disease.6 Although these meta-analyses 
included a large number of observational studies (n=37-68),3–6 these cohorts covered a much 
16 
 
earlier era (approximate data collection: 1981-19953, 1983-19974, 1980-19925, and 1985-
20026) when there may have been less emphasis on CVD risk reduction in clinical practice. 
Of the most recent CVD risk estimates from an English cohort, women were reported to have 
a higher risk for myocardial infarction after developing diabetes than men but there were no 
sex differences for other cardiovascular outcomes.23 
 
One potential explanation for these changing findings over time may be that less emphasis 
was placed on CVD risk in women with diabetes than in men.24–26 Our study uses 
contemporary data reflecting very recent clinical practice in the England where the quality 
and equity of care may have been positively influenced by recent UK management 
guidelines16 and the QOF, a pay-for-performance initiative standardising service 
improvements in primary care.13  
 
We observed that the risk of MACE was approximately 40% higher in people with T2DM 
compared to the general population (Figure 2), whereas prior studies have indicated a 2-3-
fold higher risk associated with diabetes.3–6 The lower relative risks observed in our study 
may result from differences in the study populations. We identified community-based 
patients with incident type 2 diabetes undergoing contemporary CVD risk management who 
are likely to have lower CVD risks than many described in the prior literature.3–6 For 
example, prior studies included: a) people from ethnic groups with high CVD risk (e.g. Pima 
Indians and Pacific Islanders including Melanesian and Indian Fijians); b) those with 
prevalent diabetes patients; c) younger populations (<50 years) in whom relative risks 
associated with diabetes may be higher as indicated in Supplemental Table 7; and d) higher 
risk people from outside of primary care settings. As a sensitivity analysis, we performed an 
unadjusted analysis on a prevalent T2DM cohort (Supplemental Table 14). Compared to 
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people without diabetes, the hazard ratios for MACE, MI and stroke events in the prevalent 
cohort were numerically higher for both women and men than in the incident cohort. 
However, the ratio of risks between women and men with type 2 diabetes were comparable 
and were not statistically different. 
 
Sex disparities in risk factors 
Historically, it has been thought that men with diabetes were diagnosed at an earlier age, 
were treated more actively, and were more likely to achieve recommended risk factor levels 
compared to women with diabetes.11,27 The UK National Diabetes Audit of nearly 2 million 
people studied between 2012 and 2013, showed that 58% of women and 62% of men 
received recommended care processes, and that 34% of women and 37% of men achieved 
treatment targets for HbA1c, blood pressure and cholesterol.28  
 
In our cohort, men were diagnosed about 2.6 years earlier than women and generally CVD 
risk factor management was worse in women compared to men, with the exception of 
glycaemic control. It is known that at the diagnosis of type 2 diabetes, women have higher 
levels of BMI than men.7 The higher BMI levels in women could have a role in causing 
endothelial dysfunction, hypertension, dyslipidaemia and abnormalities in fibrinolysis and 
thrombosis that contribute to CVD risk.8,29,30  
 
Sex disparities in prescribing 
The most notable gender disparities in prescribing were in relation to treatment with statins, 
ACE inhibitors and aspirin and we showed that these differences were only in part explained 
by avoidance of these medications in pre-menopausal women, in accordance with 
recommended guidelines (Supplemental Table 12).31,32 As those aged<50 accounted for only 
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17% of the total population of women at baseline, this should not have heavily impacted on 
the disparities we observed between men and women. Furthermore, the probability of lipid-
lowering therapy initiation and escalation in those with hypercholesterolaemia was 
significantly lower in women, particularly so in those with CVD, a finding which has been 
observed previously.11 The explanation behind lower prescribing in women with CVD than 
men with CVD is difficult to determine from these data and may be multifaceted. Potential 
explanations include: sex-related prescribing biases in physicians, sex-related differences in 
symptoms caused by coronary heart disease, or sex-related differences in patient attitudes and 
beliefs about their health status and requirement for medications. Further research is needed 
to better understand these findings.  
 
Strengths and limitations 
This study has several important strengths: First, we undertook a large retrospective 
population-based study using primary care data linked to hospital and mortality records 
allowing us to assess gender-related differences in CVD events, mortality, consultations and 
risk factor management associated with type 2 diabetes. Second, we used an incident cohort, 
which reflects contemporary practice and avoids the distorting influences of survival bias 
present in a prevalent cohort. Third, there were sufficient numbers of events to exclude 
clinically significant CVD risk differences between men and women developing diabetes and 
we were able to make meaningful comparisons of CVD risk factor management for up to 7 
years following diagnosis.  
 
We acknowledge some limitations: First, there was a relatively high proportion of missing 
data in non-diabetic controls for a number of CVD risk factors, along with missing data in the 
diabetes group; however we addressed this by performing multiple imputation using a 
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number of clinical characteristics to provide appropriate estimates within these populations. 
The proportion of missing data was similar in men and women with or without diabetes. 
Therefore, this should not have heavily influenced estimates of CVD risk differences in men 
and women with diabetes. Furthermore, in accordance with previous observational evidence, 
an attenuation in the effect of diabetes with age on CVD risk was observed in both men and 
women (Supplemental Table 7) providing further reassurance of the robustness of this 
data.33–35 Second, our cohort, constructed with individuals with newly-diagnosed type 2 
diabetes between 2006 and 2013, may limit comparisons with prior work that included 
individuals with prevalent diabetes. An incident cohort was sought as UK-wide changes to 
improve diabetes care were introduced over 2004-6 through the Quality and Outcomes 
Framework (QOF); therefore, prevalent diabetes diagnosed prior to this time could have 
distorted our findings. Furthermore, there are important issues around survival bias with 
prevalent cases. It is a strength that our incident cohort reflects contemporary clinical 
management practice.  Third, cohort characteristics and more active management of CVD 
risk in our contemporary cohort may explain the lower CVD risk associated with diabetes 
compared to more historical reports as described above. Fourth, the analyses based on 
patients assessed at fixed times following diagnosis (Supplemental Tables 8, 9 and 10) do not 
account for deaths and dropouts; however, loss to follow-up is unlikely to be strongly gender-
related. Furthermore, data on CVD management was limited for years 6-7 years post-
diagnosis due to the smaller sample size with longer follow-up; the average duration of 
follow-up was 3.6±2.4 years, explained by CVD and mortality events, patients entering the 
cohort later and cohort attrition. Finally, the analysis is based on data from English general 
practices and so generalisation to other healthcare systems may be limited. The sex disparity 
in cholesterol control and lipid-lowering prescribing observed in this study have been 
observed in other diabetes populations;36–38 however, comprehensive longitudinal studies of 
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all aspects of type 2 diabetes care in different countries are needed to evaluate the full extent 
of any current sex disparities in treatment and management.  
 
Clinical implications 
Reassuringly, we showed that the previously reported gender disparities in CVD risk 
associated with T2DM are not evident in contemporary English general practice. However, 
the observed gender biases in risk factor management highlight the need for closer adherence 
to clinical guidance for drug therapy, continued routine surveillance for gender-related 
prescribing biases and possibly greater uptake of professional-based interventions in the 
community to support the provision of equitable care.39,40 Particular attention is required for 
high-CVD risk women without established CVD, who may not be receive optimal 
preventative care. 
 
Conclusions 
Whilst there is clear improvement in the relative risks for CVD events, sex disparities in the 
management of CVD risk factors should prompt renewed efforts to improve the standard and 
equity of diabetes care for women and men with diabetes.
 
 
SOURCES OF FUNDING: This study was funded by Diabetes UK (BDA: 14/0004971). The 
views expressed are those of the authors and not necessarily those of Diabetes UK. The 
funders had no role in the design and conduct of the study; collection, management, analysis, 
and interpretation of the data; preparation, review, or approval of the manuscript and decision 
to submit the manuscript for publication. 
 
21 
 
DISCLOSURES: IB reports grants from the Medical Research Council, outside the submitted 
work. NS reports grants and personal fees from Boehringer Ingelheim and personal fees from 
Amgen, AstraZeneca, Eli Lilly, Janssen, Novo Nordisk and Sanofi, outside the submitted 
work. DMA reports research funding from AbbVie, Almirall, Celgene, Eli Lilly, Novartis, 
Union Chimique Belge (UCB) and the LEO Foundation outside the submitted work. MKR 
reports receiving research funding from Novo Nordisk, consultancy fees from Novo Nordisk 
and Roche Diabetes Care, and modest owning of shares in GlaxoSmithKline, outside the 
submitted work. All other authors declare no competing interests.  
 
AFFILIATIONS: From University of Manchester, Manchester, UK (A.K.W., E.K., I.B., 
D.M.A., M.K.R.); King’s College London, London, UK (R.E.); University of Liverpool, 
Liverpool, UK (I.B.); Keele University, Stoke-on-Trent, UK (M.A.M.); University of 
Glasgow, Glasgow, UK (N.S.).
22 
 
REFERENCES 
1.  American Diabetes Association. 9. Cardiovascular Disease and Risk Management: 
Standards of Medical Care in Diabetes—2018. Diabetes Care. 2018;41:S86–S104.  
2.  Diabetes UK. State of the Nation 2016. Time to take control of diabetes . Diabetes UK. 
2016 [accessed  2016 Jul 20];Available from: https://diabetes-resources-production.s3-
eu-west-1.amazonaws.com/diabetes-
storage/migration/pdf/Diabetes%2520UK%2520State%2520of%2520the%2520Nation
%25202016.pdf 
3.  Peters SAE, Huxley RR, Woodward M. Diabetes as risk factor for incident coronary 
heart disease in women compared with men: a systematic review and meta-analysis of 
64 cohorts including 858,507 individuals and 28,203 coronary events. Diabetologia. 
2014;57:1542–1551.  
4.  Peters S, Huxley R, Woodward M. Diabetes as a risk factor for stroke in women 
compared with men: A systematic review and meta-analysis of 64 cohorts, including 
775,385 individuals and 12,539 strokes. Lancet. 2014;383:1973–1980.  
5.  Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease 
associated with diabetes in men and women: meta-analysis of 37 prospective cohort 
studies. BMJ. 2006;332:73–78.  
6.  Prospective Studies Collaboration and Asia Pacific Cohort Studies Collaboration. Sex-
specific relevance of diabetes to occlusive vascular and other mortality: a collaborative 
meta-analysis of individual data from 980 793 adults from 68 prospective studies. 
Lancet Diabetes Endocrinol. 2018;6:538–546.  
7.  Peters SAE, Huxley RR, Sattar N, Woodward M. Sex Differences in the Excess Risk 
23 
 
of Cardiovascular Diseases Associated with Type 2 Diabetes: Potential Explanations 
and Clinical Implications. Curr Cardiovasc Risk Rep. 2015;9:36.  
8.  Regensteiner JG, Golden S, Huebschmann AG, Barrett-Connor E, Chang AY, Chyun 
D, Fox CS, Kim C, Mehta N, Reckelhoff JF, Reusch JEB, Rexrode KM, Sumner AE, 
Welty FK, Wenger NK, Anton B. Sex Differences in the Cardiovascular Consequences 
of Diabetes Mellitus. Circulation. 2015;132:2424–2447.  
9.  Manteuffel M, Williams S, Chen W, Verbrugge RR, Pittman DG, Steinkellner A. 
Influence of Patient Sex and Gender on Medication Use, Adherence, and Prescribing 
Alignment with Guidelines. J Womens Health. 2014;23:112–119.  
10.  Ferrara A, Mangione CM, Kim C, Marrero DG, Curb D, Stevens M, Selby J V. Sex 
Disparities in Control and Treatment of Modifiable Cardiovascular Disease Risk 
Factors Among Patients With Diabetes: Translating Research Into Action for Diabetes 
(TRIAD) Study. Diabetes Care. 2008;31:69–74.  
11.  Gouni-Berthold I, Berthold HK, Mantzoros CS, Bohm M, Krone W. Sex Disparities in 
the Treatment and Control of Cardiovascular Risk Factors in Type 2 Diabetes. 
Diabetes Care. 2008;31:1389–1391.  
12.  Eindhoven DC, Hilt AD, Zwaan TC, Schalij MJ, Borleffs CJW. Age and gender 
differences in medical adherence after myocardial infarction: Women do not receive 
optimal treatment – The Netherlands claims database. Eur J Prev Cardiol. 
2018;25:181–189.  
13.  NHS Employers. Quality and Outcomes Framework . NHS Employers. 2012 [accessed  
2016 Oct 10];Available from: http://www.nhsemployers.org/your-workforce/primary-
care-contacts/general-medical-services/quality-and-outcomes-framework 
24 
 
14.  Health and Social Care Information Centre. Quality and Outcomes Framework - 
England, 2004-05: Defining QOF indicators . NHS Digital. 2004 [accessed  2016 Sep 
12];Available from: 
https://files.digital.nhs.uk/publicationimport/pub01xxx/pub01946/qof-eng-04-05-defi-
indi-anx.pdf 
15.  NHS Employers, NHS England, British Medical Association. 2016/17 General 
Medical Services (GMS) contract Quality and Outcomes Framework (QOF) . NHS 
Employers. 2016 [accessed  2016 Sep 12];Available from: 
http://www.nhsemployers.org/~/media/Employers/Documents/Primary care 
contracts/QOF/2016-17/2016-17 QOF guidance documents.pdf 
16.  The National Institute for Health and Care Excellence (NICE). Type 2 diabetes in 
adults: management. NICE guideline NG28 . The National Institute for Health and 
Care Excellence (NICE). 2017 [accessed  2017 Aug 10];Available from: 
https://www.nice.org.uk/guidance/ng28 
17.  Springate DA, Kontopantelis E, Ashcroft DM, Olier I, Parisi R, Chamapiwa E, Reeves 
D. ClinicalCodes: An Online Clinical Codes Repository to Improve the Validity and 
Reproducibility of Research Using Electronic Medical Records. PLoS One. 
2014;9:e99825.  
18.  Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, van Staa T, Smeeth L. 
Data Resource Profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol. 
2015;44:827–836.  
19.  de Lusignan S, Khunti K, Belsey J, Hattersley A, van Vlymen J, Gallagher H, Millett 
C, Hague NJ, Tomson C, Harris K, Majeed A. A method of identifying and correcting 
25 
 
miscoding, misclassification and misdiagnosis in diabetes: a pilot and validation study 
of routinely collected data. Diabet Med. 2010;27:203–209.  
20.  Wright AK, Kontopantelis E, Emsley R, Buchan I, Sattar N, Rutter MK, Ashcroft DM. 
Life Expectancy and Cause-Specific Mortality in Type 2 Diabetes: A Population-
Based Cohort Study Quantifying Relationships in Ethnic Subgroups. Diabetes Care. 
2017;40:338–345.  
21.  Health and Social Care Information Centre. Quality and Outcomes Framework 
Achievement, prevalence and exceptions data, 2012/13Technical Annex . NHS 
Digital. 2013 [accessed  2017 Aug 10];Available from: 
https://files.digital.nhs.uk/publicationimport/pub12xxx/pub12262/qual-outc-fram-tech-
anne-2012-13-anx.pdf 
22.  The NHS Information Centre for health and social care. Quality and Outcomes 
Framework 2010-11 . NHS Digital. 2011 [accessed  2017 Aug 10];Available from: 
https://files.digital.nhs.uk/publicationimport/pub04xxx/pub04396/qof-10-11-rep.pdf 
23.  Shah AD, Langenberg C, Rapsomaniki E, Denaxas S, Pujades-Rodriguez M, Gale CP, 
Deanfield J, Smeeth L, Timmis A, Hemingway H. Type 2 diabetes and incidence of 
cardiovascular diseases: a cohort study in 1·9 million people. Lancet Diabetes 
Endocrinol. 2015;3:105–113.  
24.  Bots SH, Peters SAE, Woodward M. Sex differences in coronary heart disease and 
stroke mortality: a global assessment of the effect of ageing between 1980 and 2010. 
BMJ Glob Health. 2017;2:e000298.  
25.  Mosca L, Barrett-Connor E, Kass Wenger N. Sex/Gender Differences in 
Cardiovascular Disease Prevention. Circulation. 2011;124:2145–2154.  
26 
 
26.  Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, Newby 
LK, Piña IL, Roger VL, Shaw LJ, Zhao D, Beckie TM, Bushnell C, D’Armiento J, 
Kris-Etherton PM, Fang J, Ganiats TG, Gomes AS, Gracia CR, Haan CK, Jackson EA, 
Judelson DR, Kelepouris E, Lavie CJ, Moore A, Nussmeier NA, Ofili E, Oparil S, 
Ouyang P, Pinn VW, Sherif K, Smith SC, Sopko G, Chandra-Strobos N, Urbina EM, 
Vaccarino V, Wenger NK. Effectiveness-Based Guidelines for the Prevention of 
Cardiovascular Disease in Women—2011 Update. Circulation. 2011;123:1243–1262.  
27.  Peters SAE, Huxley RR, Sattar N, Woodward M. Sex Differences in the Excess Risk 
of Cardiovascular Diseases Associated with Type 2 Diabetes: Potential Explanations 
and Clinical Implications. Curr Cardiovasc Risk Rep. 2015;9:36.  
28.  The Health and Social Care Information Centre, Diabetes UK. National Diabetes Audit 
- 2012-2013. Report 1: Care Processes and Treatment Targets . NHS Digital. 2014 
[accessed  2017 Aug 10];Available from: 
https://files.digital.nhs.uk/publicationimport/pub14xxx/pub14970/nati-diab-audi-12-
13-care-proc-rep.pdf 
29.  Bays HE, Toth PP, Kris-Etherton PM, Abate N, Aronne LJ, Brown WV, Gonzalez-
Campoy JM, Jones SR, Kumar R, La Forge R, Samuel VT. Obesity, adiposity, and 
dyslipidemia: A consensus statement from the National Lipid Association. J Clin 
Lipidol. 2013;7:304–383.  
30.  Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity-Induced 
Hypertension. Circ Res. 2015;116:991–1006.  
31.  Barr M. Teratogen update: Angiotensin-converting enzyme inhibitors. Teratology. 
1994;50:399–409.  
27 
 
32.  The National Institute for Health and Care Excellence (NICE). Cardiovascular disease: 
risk assessment and reduction, including lipid modification. Clinical guideline 
[CG181] . The National Institute for Health and Care Excellence (NICE). 2014 
[accessed  2017 Feb 20];Available from: 
https://www.nice.org.uk/guidance/cg181/ifp/chapter/drug-treatments-to-lower-your-
cholesterol 
33.  Hirakawa Y, Ninomiya T, Kiyohara Y, Murakami Y, Saitoh S, Nakagawa H, Okayama 
A, Tamakoshi A, Sakata K, Miura K, Ueshima H, Okamura T. Age-specific impact of 
diabetes mellitus on the risk of cardiovascular mortality: An overview from the 
evidence for Cardiovascular Prevention from Observational Cohorts in the Japan 
Research Group (EPOCH-JAPAN). J Epidemiol. 2017;27:123–129.  
34.  Wannamethee SG, Shaper AG, Whincup PH, Lennon L, Sattar N. Impact of Diabetes 
on Cardiovascular Disease Risk and All-Cause Mortality in Older Men. Arch Intern 
Med. 2011;171:404–410.  
35.  Al-Saeed AH, Constantino MI, Molyneaux L, D’Souza M, Limacher-Gisler F, Luo C, 
Wu T, Twigg SM, Yue DK, Wong J. An Inverse Relationship Between Age of Type 2 
Diabetes Onset and Complication Risk and Mortality: The Impact of Youth-Onset 
Type 2 Diabetes. Diabetes Care. 2016;39:823–829.  
36.  Al-Zakwani I, Al-Mahruqi F, Al-Rasadi K, Shehab A, Al Mahmeed W, Arafah M, Al-
Hinai AT, Al Tamimi O, Al Awadhi M, Santos RD. Sex disparity in the management 
and outcomes of dyslipidemia of diabetic patients in the Arabian Gulf: findings from 
the CEPHEUS study. Lipids Health Dis. 2018;17:25.  
37.  Vimalananda VG, Miller DR, Palnati M, Christiansen CL, Fincke BG. Gender 
28 
 
Disparities in Lipid-Lowering Therapy Among Veterans With Diabetes. Womens 
Health Issues. 2011;21:S176–S181.  
38.  Zhang X, Ji L, Ran X, Su B, Ji Q, Hu D. Gender Disparities in Lipid Goal Attainment 
among Type 2 Diabetes Outpatients with Coronary Heart Disease: Results from the 
CCMR-3B Study. Sci Rep. 2017;7:12648.  
39.  Wilson A, O’Hare JP, Hardy A, Raymond N, Szczepura A, Crossman R, Baines D, 
Khunti K, Kumar S, Saravanan P, ICCD trial group. Evaluation of the clinical and cost 
effectiveness of intermediate care clinics for diabetes (ICCD): a multicentre cluster 
randomised controlled trial. PLoS One. 2014;9:e93964.  
40.  Wake DJ, He J, Czesak AM, Mughal F, Cunningham SG. MyDiabetesMyWay: An 
Evolving National Data Driven Diabetes Self-Management Platform. J Diabetes Sci 
Technol. 2016;10:1050–1058.  
 
 Figure 1. Definition of cohorts across study phases 
Phase 1: Clinical characteristics of type 2 diabetes patients and matched controls 
    Individuals with incident type 2 
             diabetes (N=79,985) 
 Individuals without diabetes 
(N=386,547) 
Inclusion criteria: 
i. First diagnosis of diabetes (type 1 diabetes 
or type 2 diabetes) recorded between 1 
January 2006 and 31 December 2013 (index 
date). Algorithm applied to classify those 
with type 2 patients  
 
ii. Must have at least 1 year prior  
registration at current practice 
 
iii. Practice and individual’s data meeting 
CPRD “up to standard” criteria for research 
 
iv. Eligible for linkage to Hospital Episode 
Statistics (HES), Office for National Statistics 
mortality data and deprivation data 
Inclusion criteria: 
i. No record of any type of diabetes 
 
ii. Must have at least 1 year prior 
registration at current practice 
 
iii. Practice and individual’s data 
meeting CPRD “up to standard” 
criteria for research 
 
iv. Eligible for linkage to Hospital 
Episode Statistics (HES), Office for 
National Statistics mortality data and 
deprivation data 
 
 
People with diabetes were matched to up to 5 people without diabetes (N=386,547) on year of birth 
(± 2 years), sex, and general practice.  
Phase 2: Major cardiovascular event (MACE) risk associated with diabetes, by sex 
 
Individuals with prevalent CVD were excluded 
 
Type 2 diabetes (N=63,718; 29,348 (46.1%) women and 34,370 (53.9%) men) and Controls 
(N=277,176; 130,524 (47.1%) women and 146,652 (52.9%) men) 
 
MACE events defined as fatal/non-fatal MI, fatal/non-fatal stroke and cardiovascular death. 
Individuals observed from the index date to the MACE endpoint date, study end date (31 
March 2015), practice’s last data collection date, death, or transfer out of practice.  
Maximum follow-up of 9 years. 
Phase 3: Sex associated cardiovascular risk factor management in type 2 diabetes  
 
Individuals with prevalent CVD were included 
 
Type 2 diabetes (N=79,985) 
Women (n=35,396; 44.3%); Men (n=44,589; 55.8%) 
 
Risk Factors, clinical characteristics and patient management data captured during 
follow-up time bands after diabetes diagnosis; Year 1 (-3 months to +12 months), Years 
2-3, Years 4-5, Years 6-7. Follow-up time captured during Phase 2. 
Minimum Standard of Care Indictors for diabetes captured during follow-up time bands 
from Years 2-3.  
 Table 1. Baseline clinical characteristics of patients with incident type 2 diabetes (T2DM) and 
matched controls without diabetes  
Data presented as N (%) or mean±SD    * total cholesterol>4mmol/L or LDL cholesterol>2mmol/L  
† HbA1c <7% (53mmol/mol); BP < 130/80mmHg; lipids: total cholesterol<4mmol/L or LDL cholesterol<2mmol/L  
‡ Current use defined as prescriptions up to 90 days prior to index date 
 
% missing data in T2DM: Obesity 12.2% (women 12.8%, men 11.7%), HbA1c 17.8% (women 17.8%, men 17.8%), Blood Pressure 29.5% 
(women 28.7%, men 30.1%), Hypercholesterolaemia 65.8% (women 66.7%, men 65.1%), Microalbuminuria/Proteinuria 46.1% (women 
46.7%, men 45.5%).  
% missing data in Controls: Obesity 66.5% (women 63.4%, men 69.0%), HbA1c 97.8% (women 97.7%, men 97.9%), Blood Pressure 
77.5% (women 74.5%, men 79.9%), Hypercholesterolaemia 96.3% (women 96.4%, men 96.2%), Microalbuminuria/Proteinuria 92.4% 
(women 91.4%, men 93.2%)
 T2DM (N=79,985) Controls (N=386,547) 
Women Men Women Men 
n, % 35,396 (44.3) 44,589 (55.8) 172,994 (44.8) 213,553 (55.3) 
Age, years 63.9±14.3 61.3±13.0 63.7±14.4 60.8±13.0 
Ethnicity     
White 28,090 (79.4) 34,251 (77.4) 127,344 (73.6) 145,259 (68.0) 
South Asian 1,544 (4.4) 1,792 (4.0) 2,960 (1.7) 3,357 (1.6) 
Black 784 (2.2) 748 (1.7) 2,226 (1.3) 2,223 (1.0) 
Other 400 (1.1) 507 (1.1) 1,545 (0.9) 1,8012 (0.8) 
Unknown 4,578 (12.9) 7,021 (15.8) 38,919 (22.5) 60,913 (28.5) 
Deprivation     
IMD 1 (least deprived) 6,330 (17.9) 8,810 (19.8) 37,354 (21.6) 48,7132 (22.8) 
IMD 2 7,624 (21.5) 10,225 (22.9) 40,447 (23.4) 50,231 (23.5) 
IMD 3 7,063 (20.0) 9,039 (20.3) 34,934 (20.2) 42,807 (20.1) 
IMD 4 7,614 (21.5) 8,961 (20.1) 33,356 (19.3) 39,8665 (18.7) 
IMD 5 (most deprived) 6,708 (19.0) 7,510 (16.8) 26,698 (15.4) 31,667 (14.8) 
Unknown 57 (0.2) 44 (0.1) 205 (0.1) 269 (0.1) 
Obese 18,517 (52.3) 22,011 (49.4) 17,815 (10.3) 18,758 (8.8) 
Smoking     
Current 11,203 (31.7)  20,883 (46.8) 45,309(26.2) 72,517 (34.0) 
Ex-smoker 9,923 (28.0) 11,564 (25.9) 47,009 (27.2) 59,265 (27.8) 
Never  1,992 (5.6) 1,468 (3.3) 9,489 (5.5) 7,669 (3.6) 
Unknown 12,278 (34.7) 10,674 (23.9) 71,187 (41.2) 74,102 (34.7) 
HbA1c >7% (53mmol/mol) 15,819 (44.7) 21,867 (49.0) - - 
HbA1c >8% (64mmol/mol) 8,844 (25.0) 13,599 (30.5) - - 
BP>140/80 mmHg 10,683 (30.2) 14,199 (31.8) 18,142 (10.5) 18,768 (8.8) 
BP>130/80 mmHg 15,577 (44.0) 19,638 (44.0) 26,636 (15.4) 26,737 (12.5) 
with target organ damage 4,537 (12.8) 3,660 (8.2) 9,393 (5.4) 6,856 (3.2) 
Hypercholesterolaemia* 8,973 (25.4) 10,244 (23.0) 5,357 (3.1) 5,958 (2.8) 
Risk factors in control †     
1 Risk factor in control 14,617 (41.3) 17,531 (39.3) 154,999 (89.6) 195,919 (91.7) 
2 Risk factors in control 4,815 (13.6) 5,813 (13.0) 17,693 (10.2) 16,861 (7.9) 
3 Risk factors in control 503 (1.4) 820 (1.8) 302 (0.2) 773 (0.4) 
Cardiovascular Disease     
Coronary heart disease 3,910 (11.1) 7,506 (16.8) 10,767 (6.2) 20,096 (9.4) 
Cerebrovascular disease 2,175 (6.1) 2,737 (6.1) 7,563 (4.3) 9,369 (4.4) 
Peripheral vascular disease 946 (2.7) 1,808 (4.1) 2,631 (1.5) 4,813 (2.3) 
Chronic kidney disease 7,921 (22.4) 5,974 (13.4) 21,238 (12.3) 16,162 (7.6) 
Microalbuminuria or 
proteinuria 
3,416 (9.7) 5,923 (13.3) 2,735 (1.6) 3,726 (1.7) 
Peripheral neuropathy 343 (1.0) 527 (1.2) 565 (0.3) 789 (0.4) 
Retinopathy 1,278 (3.6) 1,825 (4.1) 25 (0.01) 23 (0.01) 
History of pregnancy 10,312 (29.1) - 50,399 (29.1) - 
Hormone-replacement 
therapy (current use) ‡ 
451 (1.3) - 3,079 (1.8) - 
Oral contraceptives 
(current use) ‡ 
397 (1.1) - 1,380 (0.8) - 
 Figure 2. Unadjusted and multivariable-adjusted hazard ratios for incident CVD 
comparing people with and without T2DM by sex, and ratio of risk (RRR) for women 
relative to men  
 
 
 
 
 
 
 
 
 
 
 
 
Adjusted for age, ethnicity, deprivation, general practice, calendar year, baseline: 
smoking, obesity, hypertension, hypercholesterolaemia, comorbidities and time-
varying: smoking, obesity, hypertension, hypercholesterolaemia, raised HbA1c. 
 Ratio of relative risks (RRR) greater than 1 indicates an excess risk for incident 
CVD in women who developed diabetes compared to men who developed diabetes. 
CVD indicates cardiovascular disease; T2DM, type 2 diabetes; MACE, major 
adverse cardiac events; MI, myocardial infarction; HR, hazard ratio; CI, confidence 
interval. 
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 Figure 3. Comparison of the proportion of men and women undergoing intensification of drug regimens in relation to the time that their 
risk factors (HbA1c, BP, lipids) were above threshold values: A) HbA1c >7% (53mmol/mol); B) BP >140/80 mmHg in patients with 
prevalent CVD, C) LDL-cholesterol >2 mmol/L or total cholesterol >4 mmol/L in patients with prevalent CVD, D) LDL-cholesterol >2 
mmol/L or total cholesterol >4 mmol/L in patients without prevalent CVD 
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